151 related articles for article (PubMed ID: 12670316)
1. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze.
Rodgers RJ; Haller J; Halasz J; Mikics E
Eur J Neurosci; 2003 Mar; 17(6):1279-86. PubMed ID: 12670316
[TBL] [Abstract][Full Text] [Related]
2. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice.
Rodgers RJ; Evans PM; Murphy A
Behav Pharmacol; 2005 Sep; 16(5-6):405-13. PubMed ID: 16148445
[TBL] [Abstract][Full Text] [Related]
3. Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plus-maze-naïve or plus-maze-experienced mice.
Rodgers RJ; Wright FL; Snow NF; Taylor LJ
Behav Brain Res; 2013 Apr; 243():213-9. PubMed ID: 23333844
[TBL] [Abstract][Full Text] [Related]
4. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety.
Haller J; Bakos N; Szirmay M; Ledent C; Freund TF
Eur J Neurosci; 2002 Oct; 16(7):1395-8. PubMed ID: 12405999
[TBL] [Abstract][Full Text] [Related]
5. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.
Haller J; Varga B; Ledent C; Freund TF
Behav Pharmacol; 2004 Jul; 15(4):299-304. PubMed ID: 15252281
[TBL] [Abstract][Full Text] [Related]
6. Anxioselective profile of glycineB receptor partial agonist, D-cycloserine, in plus-maze-naïve but not plus-maze-experienced mice.
Rodgers RJ; Howard K; Stewart S; Waring P; Wright FL
Eur J Pharmacol; 2010 Nov; 646(1-3):31-7. PubMed ID: 20727880
[TBL] [Abstract][Full Text] [Related]
7. Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze.
Holmes A; Rodgers RJ
Neurosci Biobehav Rev; 1999 Nov; 23(7):971-80. PubMed ID: 10580311
[TBL] [Abstract][Full Text] [Related]
8. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
9. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze.
Rodgers RJ; Gentsch C; Hoyer D; Bryant E; Green AJ; Kolokotroni KZ; Martin JL
Behav Brain Res; 2004 Sep; 154(1):183-92. PubMed ID: 15302124
[TBL] [Abstract][Full Text] [Related]
10. The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze.
Takahashi RN; Pamplona FA; Fernandes MS
Neurosci Lett; 2005 Jun; 380(3):270-5. PubMed ID: 15862900
[TBL] [Abstract][Full Text] [Related]
11. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
Griebel G; Stemmelin J; Scatton B
Biol Psychiatry; 2005 Feb; 57(3):261-7. PubMed ID: 15691527
[TBL] [Abstract][Full Text] [Related]
12. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
Navarro M; Hernández E; Muñoz RM; del Arco I; Villanúa MA; Carrera MR; Rodríguez de Fonseca F
Neuroreport; 1997 Jan; 8(2):491-6. PubMed ID: 9080435
[TBL] [Abstract][Full Text] [Related]
13. Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test.
Biala G; Kruk M; Budzynska B
J Physiol Pharmacol; 2009 Jun; 60(2):113-22. PubMed ID: 19617654
[TBL] [Abstract][Full Text] [Related]
14. Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test.
Holmes A; Iles JP; Mayell SJ; Rodgers RJ
Behav Brain Res; 2001 Aug; 122(2):159-67. PubMed ID: 11334646
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic-like properties of the anandamide transport inhibitor AM404.
Bortolato M; Campolongo P; Mangieri RA; Scattoni ML; Frau R; Trezza V; La Rana G; Russo R; Calignano A; Gessa GL; Cuomo V; Piomelli D
Neuropsychopharmacology; 2006 Dec; 31(12):2652-9. PubMed ID: 16541083
[TBL] [Abstract][Full Text] [Related]
16. Sacred Maya incense, copal (Protium copal - Burseraceae), has antianxiety effects in animal models.
Merali Z; Cayer C; Kent P; Liu R; Cal V; Harris CS; Arnason JT
J Ethnopharmacol; 2018 Apr; 216():63-70. PubMed ID: 29414121
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of fatty acid amide hydrolase by URB597 attenuates the anxiolytic-like effect of acetaminophen in the mouse elevated plus-maze test.
Zaitone SA; El-Wakeil AF; Abou-El-Ela SH
Behav Pharmacol; 2012 Aug; 23(4):417-25. PubMed ID: 22750843
[TBL] [Abstract][Full Text] [Related]
18. Mu-opioid receptor knockout mice are more sensitive to chlordiazepoxide-induced anxiolytic behavior.
Wang KC; Lee YJ; Fan LW; Yang PP; Tao PL; Ho IK; Tien LT
Brain Res Bull; 2013 Jan; 90():137-41. PubMed ID: 23142328
[TBL] [Abstract][Full Text] [Related]
19. Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice.
Balerio GN; Aso E; Maldonado R
Psychopharmacology (Berl); 2006 Mar; 184(3-4):504-13. PubMed ID: 16416159
[TBL] [Abstract][Full Text] [Related]
20. Effects of plus-maze experience and chlordiazepoxide on anxiety-like behavior and serotonin neural activity in the dorsal raphe nucleus in rats.
Grahn RE; Kalman BA; Vlasaty JA; Perna JA; Nevins-Herbert C; Patton SM; Barison LK
Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):208-219. PubMed ID: 30169377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
